|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||26.71 - 26.99|
|52 Week Range||24.98 - 29.50|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.00%|
A federal judge signaled he would approve a $290 million settlement reached by Pershing Square, Valeant and the shareholders of Allergan who had alleged the two firms improperly profited from their failed ...
Pershing Square Holdings, the hedge fund operated by noted activist investor Bill Ackman, on Wednesday announced it was slashing its management fees, a move related to the settlement of two class-action ...
Exchange traded funds tied to marijuana skidded on Thursday on a report that Attorney General Jeff Sessions planned to roll back the measure that encouraged more states in recent years to legalize usage of the plant.
Hedge funder Bill Ackman and Valeant Pharmaceuticals will pay $290 million to settle claims from shareholders in Allergan they engaged in insider trading when pressing a takeover of the botox-maker in 2014. The settlement means Valeant likely cost Pershing $4 billion.
Pershing Square Capital Management and Valeant Pharmaceuticals are paying $290 million to settle a lawsuit that alleged their trading in Allergan was illegal, allowing William Ackman to put behind him ...
Pershing Square said it decided to raise its share of the settlement to 66.8 percent, or $193.75 million, in a bid to quickly wind up the litigation, which it claimed had "no merit". "We decided, however, that it was in the best interest of our investors to settle the case now instead of continuing to spend substantial time and resources pursuing the litigation," said Pershing Square CEO Bill Ackman. The hedge fund said Valeant will now pay around 33 percent, or $96.25 million, of the settlement costs.
Activist investor Bill Ackman’s Pershing Square Holdings Ltd. and Valeant Pharmaceuticals International Inc. agreed to pay $290 million to settle investor claims that they engaged in insider trading in ...
Valeant Pharmaceuticals International Inc. said Friday that all parties in the Allergan Inc. shareholder securities litigation have agreed to resolve the claims that total $290 million, subject to court ...
A preliminary ruling from a federal judge against William Ackman, his hedge fund and Valeant in an insider-trading case could trigger a settlement between the activist investor and shareholders of Allergan....
Triple-leveraged ETFs – funds that mainly use futures to ratchet up the exposure to a specific asset – have long been considered one of Wall Street’s riskiest products. This week, those funds take a back seat to the newly launched quadruple-leveraged exchange-traded notes brought to the market by Citigroup.
AdvisorShares, an exchange traded fund provider known for its actively managed investment options, has launched a new ETF that capitalizes on vice and also one among the first to include targeted exposure ...
BETHESDA, Md., Dec. 11, 2017 /PRNewswire/ -- AdvisorShares, a leading sponsor of actively managed exchange-traded funds (ETFs), announced today that the AdvisorShares Vice ETF (Ticker: ACT) will begin trading on Tuesday, December 12, 2017. ACT becomes the first ETF – among both passively managed and actively managed strategies – that provides concentrated exposure to select companies associated with alcohol, cannabis and tobacco. ACT's portfolio management team carries extensive experience in the capital markets and a well-established expertise of investing in this area of the equity markets, which includes the founder and original portfolio manager of the Vice Fund mutual fund (VICEX).
Teva Pharmaceutical Industries , the world's largest generic drugmaker, said on Wednesday it was looking for a buyer for its Medis business as it sells assets to pare down its debt burden. Teva, which last week reported a drop in second-quarter results and cut its outlook and dividend, acquired Iceland-based Medis as part of its acquisition of Actavis last year. "Teva is looking at every opportunity to focus our business and streamline operations, processes and structure," Teva said in an emailed statement to Reuters.
Eli Lilly and Co won a years-long patent dispute with Actavis on Friday after the UK Supreme Court ruled that the generic drugmaker's versions of Lilly's top-selling cancer drug Alimta directly infringe on certain Lilly patents in Britain, France, Italy and Spain. Teva Pharmaceutical Industries Ltd owns the generic versions of Alimta in question after buying Allergan Plc's generic business Actavis last August.
LONDON (AP) — Britain's Supreme Court has ruled in favor of Eli Lilly and Co. in a patent dispute with generic drug-maker Actavis over Lilly's Alimta cancer treatment.
Lilly sued Actavis, saying its generic product would still infringe on Lilly's vitamin regimens regardless of any dilution.
Eli Lilly & Co. won a patent dispute with Actavis at the U.K.’s top court, marking a victory in a long-running legal campaign to defend its third best-selling drug, Alimta, from rival products.
Israel-based Teva Pharmaceutical Industries reported a smaller-than-expected fall in first-quarter profit on Thursday, with sales boosted by its $40.5 billion acquisition last year of generics drug business Actavis. Teva was left without a permanent chief executive in February after Erez Vigodman stepped down, leaving new management to try to restore confidence in the world's biggest generic drugmaker after a series of missteps. Teva on Thursday named Michael McClellan as interim CFO, effective July 1.
Allergan sold its generics business Actavis to Teva in August 2016 for $33 billion in cash and 100 million shares of the Israeli generic drugmaker, worth around $5.3 billion at the time. Under the terms of the deal, Allergan agreed to hold on to the shares for at least one year. Teva has struggled since then, and the company's chief executive stepped down in February after sharp criticism for a string of costly acquisitions and delayed drug launches.
Botox-maker Allergan Plc posted a first-quarter loss on Tuesday as it took a nearly $2 billion write-down on the value of its stake in Teva Pharmaceutical Industries, which has lost more than 40 percent of its value since last year. Allergan sold its generics business Actavis to Teva in August 2016 for $33 billion in cash and 100 million shares of the Israeli generic drugmaker, worth around $5.3 billion at the time. Under the terms of the deal, Allergan agreed to hold on to the shares for at least one year.
Pershing Square is setting aside $75 million to cover a class action insider trading lawsuit surrounding its efforts to merge Allergan with now-embattled Valeant, which made Bill Ackman $1.1 billion according to Forbes.